PMVP: רווח נקי למניה ב-12 החודשים האחרונים pmvpharma.com
PMV Pharmaceuticals is developing targeted oncology therapies for p53 protein regeneration, which promises colossal profits upon successful testing. This 12-month net income per share chart visualizes this trajectory, where -1.52 indicates the current level. PMV Pharmaceuticals monetizes unique patents through partnerships with pharma behemoths, and its R&D pipeline featuring the PC14586 molecule is currently undergoing intensive Phase II clinical trials.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_PMVP_-_PMV-Pharmaceuticals_-_Earnings-per-share-for-the-last-four-quarters "PMV Pharma - רווח נקי למניה (EPS TTM) PMVP (תקופה 04.07.2022 - 15.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת PMV Pharmaceuticals
PMV Pharmaceuticals (PMVP) occupies a unique niche in oncology thanks to its proprietary p53 protein restoration technology. This metric measures the final profit attributable to a single common share per year, excluding the impact of capital dilution. An analysis of the net income per share TTM fundamental indicator allows for an assessment of the efficiency of monetizing the company's technological advantage. Growth in this indicator confirms the viability of the business model during the drug development period. Positive dynamics signal that PMV Pharmaceuticals (PMVP) is transitioning to a stage of real capitalization of its innovations.
